Chimerion Biotechnology Inc is categorized under Commercial Biotechnical Research in Cambridge, MA and active since 2012.
Chimerion Biotechnology Inc was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Jeffrey Way at the company’s single location by writing to 108 Fayerweather St, Cambridge, Massachusetts MA 02138 or by phoning (617) 372-2019. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Chimerion Biotechnology Inc |
Contact Person: | Jeffrey Way |
Address: | 108 Fayerweather St, Cambridge, Massachusetts 02138 |
Phone Number: | (617) 372-2019 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2012 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Commercial Biotechnical Research |
SIC Code: | 8731 |
NAICS Code: | 541711 |
Share This Business: |
Chimerion Biotechnology Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jeffrey Way for inquiries that concern Chimerion Biotechnology Inc by calling the company number (617) 372-2019, as your correspondence is most welcome. Additionally, the physical location of the single location of Chimerion Biotechnology Inc can be found at the coordinates 42.382642,-71.136851 as well as the street address 108 Fayerweather St in Cambridge, Massachusetts 02138.
For its online presence, you may visit Chimerion Biotechnology Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.